Clinical Trials
388
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (337 trials with phase data)• Click on a phase to view related trials
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT07024615
- Locations
- 🇺🇸
Duke University Medical Center - Duke Cancer Center, Durham, North Carolina, United States
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Conditions
- Prostate CancerMetastatic Castration-Resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
- Interventions
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT07005154
- Locations
- 🇺🇸
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
🇯🇵JP81002, Koto-ku, Tokyo, Japan
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or CancerMetastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- Drug: Folinic acid (leucovorin or local equivalent)Drug: Placebo
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT06901531
- Locations
- 🇰🇷
KR82001, Seoul, Korea, Republic of
🇰🇷KR82006, Seoul, Korea, Republic of
🇰🇷KR82012, Seoul, Korea, Republic of
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
- Conditions
- Metastatic Urothelial Carcinoma
- Interventions
- Drug: Enfortumab Vedotin
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06862219
- Locations
- 🇮🇳
IN91005, Varanasi, Uttar Pradesh, India
🇮🇳IN91012, Ahmedabad, India
🇮🇳IN91010, Bhubaneswar, India
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause
- First Posted Date
- 2025-02-06
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06812754
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
🇨🇳Capital Medical University (CMU) - Beijing Shijitan Hospital, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 38
- Next